Patents by Inventor Leif Erik Sander

Leif Erik Sander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bacterial RNAs as vaccine adjuvants
    Patent number: 10588964
    Abstract: The invention features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: March 17, 2020
    Assignee: Cornell University
    Inventors: Julie Magarian Blander, Leif Erik Sander
  • BACTERIAL RNAS AS VACCINE ADJUVANTS
    Publication number: 20180326050
    Abstract: The invention features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants.
    Type: Application
    Filed: November 10, 2017
    Publication date: November 15, 2018
    Inventors: Julie Magarian Blander, Leif Erik Sander
  • Bacterial RNAs as vaccine adjuvants
    Patent number: 9844592
    Abstract: The disclosure features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mRNA (e.g., bacterial mRNA), as well as the methods of using the vaccine compositions. Further disclosed are the structural features of the prokaryotic mRNA used as the adjuvants.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: December 19, 2017
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Julie Magarian Blander, Leif Erik Sander
  • BACTERIAL RNAs AS VACCINE ADJUVANTS
    Publication number: 20140186398
    Abstract: The disclosure features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mRNA (e.g., bacterial mRNA), as well as the methods of using the vaccine compositions. Further disclosed are the structural features of the prokaryotic mRNA used as the adjuvants.
    Type: Application
    Filed: July 17, 2012
    Publication date: July 3, 2014
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Julie Magarian Blander, Leif Erik Sander